Key facts
- This page summarizes Harold E. Selick's Form 4 filing for Protagonist Therapeutics, Inc (PTGX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Apr 2023, 19:18.
Harold E. Selick - 10 Apr 2023 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)
- Reporting relationship
- Director
- Issuer ticker
- PTGX
- Reported as of
- 10 Apr 2023
- Net transaction value
- +$5,391
- SEC form
- 4
- Accepted by SEC
- 11 Apr 2023, 19:18:54 UTC
- Prior SEC filing
- 18 Jan 2023
- Next SEC filing
- 31 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Asif Ali, Attorney-in-Fact for Harold E. Selick
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Harold E. Selick filed Form 4 for Protagonist Therapeutics, Inc (PTGX) on 11 Apr 2023.
Change
- Previous filing in this sequence was filed on 18 Jan 2023.
- Current net transaction value: +$5,391.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PTGX
transaction
Common Stock
Options Exercise
- Transaction value
- $5,391
- Shares
- +6,196
- Change %
- +40%
- Price
- $0.8700
- Shares after
- 21,506
- Date
- 10 Apr 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PTGX
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -6,196
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 10 Apr 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,196
- Exercise price
- $0.8700
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the "Lock-up Date") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date.
Footnote F2
The stock option is vested in full.